• The Park

    The Park

    Our values
    Testimonials
    Getting here
    2040 Vision

    See our plans to become a pioneering research and innovation district

    Learn More
    Getting here

    Milton Park has unrivalled transport links by bus, train, bike and road.

    Learn More
  • Find a workspace
    R&D workspace

    Research and development workspaces for innovation and manufacturing

    Industrial space

    High-tech industrial units now available in Oxfordshire

    Lab space

    Fitted or unfitted laboratory space in Oxfordshire

    Co-working office space at Bee House

    Welcome to Oxfordshire’s largest and buzziest co-working space

    Serviced office space

    Flexible office space for agile businesses in Oxfordshire

    Office space

    Readily available office spaces for companies of all sizes

    Amenity space

    Food & beverage, retail and leisure spaces, including the new Signal Yard development.

    Meeting and conference space

    Available for both Milton Park occupiers and off-park companies to hire.

    Design and build

    Looking for landmark laboratory, flagship head office or bespoke R&D workspace? We can help…

    Learn more
    Future developments

    Discover future developments at Milton Park including Nebula and Signal Yard

    Learn more
    Signal Yard

    17 state-of-the-art units offering a vibrant mix of food & beverage, retail and leisure venues

    Learn more
  • Community
    Signal Yard

    17 state-of-the-art units offering a vibrant mix of food & beverage, retail and leisure venues

    Learn more

    Community

    Community
    Amenities
    Who's here
    Find a job
    Meeting and Conference Space

    Available for both Milton Park occupiers and off-park companies to hire

    Learn more
  • News
  • Events
  • About us
    Getting here

    Milton Park has unrivalled transport links by bus, train, bike and road.

    Learn more

    About us

    About us
    Meet the team
    Local engagement
    Sustainability
  • Contact
  • The Park
    back

    The Park

    back

    The Park

    Our values
    Testimonials
    Getting here

    2040 Vision

    Getting here

  • Find a workspace
    back

    Find a workspace

    Search by type

    back

    Search by type

    R&D workspace
    Industrial space
    Lab space
    Co-working office space at Bee House
    Serviced office space
    Office space
    Amenity space
    Meeting and conference space

    Design and build

    Future developments

    Signal Yard

  • Community
    back

    Community

    back

    Community

    Community
    Amenities
    Who's here
    Find a job

    Meeting and Conference Space

  • News
    back

    News

  • Events
    back

    Events

  • About us
    back

    About us

    About us
    Meet the team
    Local engagement
    Sustainability
  • Contact
    back

    Contact

HomeNewsOccupier News

News  /  Occupier News

Innovation community news – March

Published on 28 March 2025

Back to results

Image caption: ©Oxitec Ltd. All Rights Reserved.

News and announcements from Milton Park based companies:

  • Immunocore presents data for HIV functional cure
  • Gylden Pharma plans clinical trials
  • Nium nominated for The Earthshot Prize 2025 
  • Oxitec scales innovation for impact
  • Summit Therapeutics announces collaboration with Pfizer
Immunocore presents data for HIV functional cure

Milton Park-based Immunocore has presented initial data for a functional cure that could enable people with HIV to remain healthy without lifelong antiretroviral treatment, which currently involves a combination of drugs to stop the virus replicating in the body. 

The data presented at the Conference on Retroviruses and Opportunistic Infections in San Francisco, shows that IMC-M113V, the first T-cell receptor bispecific therapy to target HIV in the clinic, is well-tolerated in the multiple ascending dose* (MAD) portion of is Phase 1/2 trial. 

*A multiple ascending dose is a type of trial designed for safety 

Dr Beatriz Mothe, Associate Investigator, HIV Unit, Infectious Diseases Department, IrsiCaixa, commented: “I am encouraged by the safety profile and initial signals of anti-viral activity of IMC-M113V in the Phase 1/2 trial.

“I look forward to further data from the trial at higher doses, as part of wider efforts to find solutions that could enable people with HIV to remain healthy without lifelong antiretroviral treatment.”

Gylden Pharma plans clinical trials

Clinical-stage biotechnology company based at Milton Park, Gylden Pharma has announced that clinical trials are planned to evaluate its T-cell priming (TcP) candidates against Dengue fever, an infection spread by mosquitoes, in a Phase II study, as well as  disease caused by Betacoronaviruses, which pose significant epidemic or pandemic risk, in Phase I-II and Phase II trials. 

Professor Thomas Rademacher, Co-founder, Executive Director and CEO of Gylden Pharma, commented: “We begin 2025 having achieved substantial milestones in 2024 and anticipating major innovations in how the world approaches infectious diseases and pandemic threats.”

Nium nominated for The Earthshot Prize 2025

Milton Park-based nanotechnology start-up Nium, has been nominated for The Earthshot Prize, one of the world’s most prestigious environmental awards dedicated to accelerating groundbreaking solutions that can repair and regenerate the planet.  

Launched by Prince William and Sir David Attenborough in 2020, the Prize’s five winners will be awarded £1 million to scale their innovations and drive climate impact.  

Lewis Jenkins, Co-Founder of Nium, commented: “We are incredibly proud and excited to be in the nominations for the 2025 Earthshot Prize.

“When we founded Nium, a company with a mission to eliminate emissions, we aspired to be recognised by Earthshot, so this is a dream come true for our small team.

“We have worked hard to get this nomination and are grateful to all the nominees and supporters who put us here.”

Oxitec scales innovation for impact

Oxitec is collaborating with industry leaders across Asia to advance and scale the next generation of biological solutions to combat the escalating threat of vector-borne diseases*. 

The Milton Park-based biotech shared that its Friendly™ mosquitoes are already protecting communities in Brazil from dengue-spreading Aedes aegypti (also known as the yellow fever mosquito), demonstrating a proven, safe and effective biological control approach. Oxitec is now scaling Sparks™, harnessing Wolbachia, a dengue-blocking technology, to expand impact across Asia. 

*A vector-borne disease results from an infection transmitted to humans and other animals by blood-feeding arthropods such as mosquitoes. 

Summit Therapeutics announces collaboration with Pfizer

In a step forward in tackling cancer tumours, Summit Therapeutics has announced it will be collaborating with global biopharmaceutical company, Pfizer for clinical trials evaluating potential first-in-class investigational antibody, Ivonescimab, in combination with antibody drug conjugates* (ADCs), in unique solid tumour settings. 

*Antibody drug conjugates are a combination of chemotherapy and targeted therapy to treat certain tumours 

Bob Duggan and Dr. Maky Zanganeh, CO-CEOs at Summit Therapeutics, commented: “As we seek to accelerate the development of our potentially transformative ivonescimab across non-small cell lung cancer and other solid tumour settings, this collaboration will allow us to quickly advance beyond our promising late-stage development plan to evaluate ivonescimab in combination with some of the most innovative ADCs from Pfizer.”

Clinical trials are expected to begin mid-2025.

Milton Park

Discover other companies based at Milton Park.

Who’s here
Share this article

Related news

News
News / Amenities

Progress continues at Signal Yard

Published on 29 May 2025
News / Business

A string of award shortlists

Published on 28 May 2025
News / Sustainability

Exciting rewards for greener travel

Published on 23 May 2025

Sign up to our newsletter

Subscribe

Subscribe to the Milton Wonder newsletter for latest news, events and competitions.

"*" indicates required fields

What best describes your relationship with Milton Park?*
Please select all that apply
Consent*

We’re here to help
Call us on +44 (0)1235 865 555

Or follow
us on
  • Privacy Policy
  • Cookie Preferences

®Milton Park is a registered trademark, owned by MEPC Milton GP Limited, Bee House, 140 Eastern Avenue, Milton Park, Oxfordshire OX14 4SB

Registered Office: MEPC Milton GP Ltd, Sixth Floor, 150 Cheapside, London EC2V 6ET

Registered in England, No. 7669538 | ® Copyright MEPC Milton GP Ltd 2025